Physician profile
Paul Peterson
NPI 1730127564
$3,389.44
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,714 · 2020: $1,370 · 2021: $305.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $706.07 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $511.86 | 2019-2021 | |
| Lilly USA, LLC | $267.61 | 2019-2021 | |
| Glaxosmithkline, LLC. | $234.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.02 | 2019-2021 | |
| Pfizer INC. | $211.19 | 2019-2021 | |
| Amarin Pharma, INC. | $195.59 | 2019-2021 | |
| Amgen INC. | $162.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $135.10 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $114.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $91.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.80 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $60.09 | 2019-2020 | |
| Astellas Pharma US INC | $54.28 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52.85 | 2021 | |
| Allergan, INC. | $44.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $42.54 | 2019-2020 | |
| Eisai INC. | $39.83 | 2019 | |
| Mannkind Corporation | $28.10 | 2019 | |
| Ibsa Pharma INC. | $27.84 | 2019 | |
| Gebauer Company | $19.84 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.11 | 2019 | |
| Currax Pharmaceuticals LLC | $12.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.